{{Drugbox
| IUPAC_name = (3''S'')-3-[4-(Butylsulfanyl)-1,2,5-thiadiazol-3-yl]quinuclidine
| image = Vedaclidine.svg
| width = 175

<!--Clinical data-->
| tradename =
| pregnancy_category =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number = 141575-52-2
| ATC_prefix = None
| ATC_suffix =
| PubChem = 9889093
| ChemSpiderID = 8064764
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 98IW5HAV1N
| ChEMBL = 136807

<!--Chemical data-->
| C=13 | H=21 | N=3 | S=2 
| molecular_weight = 283.455 g/mol
| SMILES = CCCCSC1=NSN=C1[C@@H]2CN3CCC2CC3
| StdInChI = 1S/C13H21N3S2/c1-2-3-8-17-13-12(14-18-15-13)11-9-16-6-4-10(11)5-7-16/h10-11H,2-9H2,1H3/t11-/m1/s1
| StdInChIKey = WZZPXVURFDJHGI-LLVKDONJSA-N
| synonyms = (''S'')-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]quinuclidine
}}

'''Vedaclidine''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 38 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL38.pdf | publisher = World Health Organization | accessdate = 18 November 2016 | date = 1997}}</ref>{{rp|180}} codenamed '''LY-297,802''', '''NNC 11-1053''') is a novel [[analgesic]] [[drug]] which acts as a mixed [[agonist–antagonist]] at [[muscarinic acetylcholine receptors]], being a potent and selective [[agonist]] for the [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] and [[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]] subtypes, yet an [[Antagonist (pharmacology)|antagonist]] at the [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]], [[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]] and [[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]] subtypes.<ref>{{cite journal | last1 = Shannon | first1 = HE | last2 = Womer | first2 = DE | last3 = Bymaster | first3 = FP | last4 = Calligaro | first4 = DO | last5 = DeLapp | first5 = NC | last6 = Mitch | first6 = CH | last7 = Ward | first7 = JS | last8 = Whitesitt | first8 = CA | last9 = Swedberg | first9 = MD ''et al.'' | last10 = Sheardown | first10 = M. J. | last11 = Fink-Jensen | first11 = A | last12 = Olesen | first12 = P. H. | last13 = Rimvall | first13 = K | last14 = Sauerberg | first14 = P | year = 1997 | title = In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist | url = | journal = Life Sciences | volume = 60 | issue = 13–14| pages = 969–76 | pmid = 9121363 | display-authors = 8 | doi=10.1016/s0024-3205(97)00036-2}}</ref><ref>{{cite journal | last1 = Womer | first1 = DE | last2 = Shannon | first2 = HE | title = Reversal of pertussis toxin-induced thermal allodynia by muscarinic cholinergic agonists in mice | journal = Neuropharmacology | volume = 39 | issue = 12 | pages = 2499–504 | year = 2000 | pmid = 10974334 | doi=10.1016/S0028-3908(00)00068-X}}</ref> It is orally active and an effective analgesic over 3× the potency of [[morphine]], with side effects such as [[Hypersalivation|salivation]] and [[tremor]] only occurring at many times the effective analgesic dose.<ref>{{cite journal | last1 = Swedberg | first1 = MD | last2 = Sheardown | first2 = MJ | last3 = Sauerberg | first3 = P | last4 = Olesen | first4 = PH | last5 = Suzdak | first5 = PD | last6 = Hansen | first6 = KT | last7 = Bymaster | first7 = FP | last8 = Ward | first8 = JS | last9 = Mitch | first9 = CH ''et al.'' | last10 = Calligaro | first10 = D. O. | last11 = Delapp | first11 = N. W. | last12 = Shannon | first12 = H. E. |date=May 1997 | title = Butylthio[2.2.2] (NNC 11-1053/LY297802)  an orally active muscarinic agonist analgesic | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 281 | issue = 2| pages = 876–83 | pmid = 9152397 | display-authors = 8 }}</ref><ref>{{cite journal | last1 = Shannon | first1 = HE | last2 = Sheardown | first2 = MJ | last3 = Bymaster | first3 = FP | last4 = Calligaro | first4 = DO | last5 = Delapp | first5 = NW | last6 = Gidda | first6 = J | last7 = Mitch | first7 = CH | last8 = Sawyer | first8 = BD | last9 = Stengel | first9 = PW ''et al.'' | last10 = Ward | first10 = J. S. | last11 = Wong | first11 = D. T. | last12 = Olesen | first12 = P. H. | last13 = Suzdak | first13 = P. D. | last14 = Sauerberg | first14 = P | last15 = Swedberg | first15 = M. D. |date=May 1997 | title = Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053)  a novel analgesic with mixed muscarinic receptor agonist and antagonist activity | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 281 | issue = 2| pages = 884–94 | pmid = 9152398 | display-authors = 8 }}</ref><ref>{{cite journal | last1 = Shannon | first1 = HE | last2 = Jones | first2 = CK | last3 = Li | first3 = DL | last4 = Peters | first4 = SC | last5 = Simmons | first5 = RM | last6 = Iyengar | first6 = S | title = Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats | journal = Pain | volume = 93 | issue = 3 | pages = 221–7 | year = 2001 | pmid = 11514081 | doi=10.1016/S0304-3959(01)00319-0}}</ref> Human trials showed little potential for development of dependence or abuse,<ref>{{cite journal | last1 = Petry | first1 = NM | last2 = Bickel | first2 = WK | last3 = Huddleston | first3 = J | last4 = Tzanis | first4 = E | last5 = Badger | first5 = GJ | title = A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users | journal = Drug and Alcohol Dependence | volume = 50 | issue = 2 | pages = 129–36 | year = 1998 | pmid = 9649964 | doi=10.1016/S0376-8716(98)00026-X}}</ref> and research is continuing into possible clinical application in the treatment of [[neuropathic pain]] and [[cancer pain]] relief.<ref>{{cite journal | last1 = Tata | first1 = AM | title = Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy | journal = Recent patents on CNS drug discovery | volume = 3 | issue = 2 | pages = 94–103 | year = 2008 | pmid = 18537768 | doi = 10.2174/157488908784534621 }}</ref>

== See also ==
* [[Aceclidine]]
* [[Talsaclidine]]

== References ==
{{Reflist|2}}

{{Analgesics}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Analgesics]]
[[Category:Muscarinic agonists]]
[[Category:Muscarinic antagonists]]
[[Category:Quinuclidines]]
[[Category:Thiadiazoles]]
[[Category:Thioethers]]